Colloidal Silver, Treatment of COVID-19

• Status: Recruiting
• Trial end date: 2021-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Noble metals such as gold and silver have been appreciated for millennia not only for their beauty but also for their ability to fight diseases.

Silver nanoparticles (AgNPs) have been employed as chemical drugs thanks to their unique physiochemical and chemical properties as well as biological features, such as anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial activities I

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hôpital Universitaire Sahloul

Criteria

Inclusion Criteria:

• Inclusion of any patient, over the age of 18, consulting the Sahloul emergencies, Sousse for symptoms of COVID -19 dating less than 10 days and having a positive COVID-19 on the PCR test and typical scanner.

Exclusion Criteria:

• Any pregnant or breastfeeding woman

• patient with an expectation of survival of less than 24 hours

• Dyspnea leading to heart failure

• Hepatic insufficiency

• Chronic respiratory failure

• Renal failure, clearance <20ml • min-1 • 1.73 • m-²